AstraZeneca Pharma India Limited announced key appointments and promotions within its Senior Management team, effective April 1, 2026. Dr. Shashank Srinivasan has been appointed as Medical Director – Oncology Business Unit. Simultaneously, Mr. Venkat Natarajan has been promoted from Lead – Market Access to Director – Market Access Business Unit, reflecting his contributions to strategic access initiatives.
Key Personnel Updates Effective April 1, 2026
AstraZeneca Pharma India Limited has approved significant changes to its Senior Management Personnel structure, announced on March 31, 2026, following recommendations from the Nomination and Remuneration Committee. These changes are designed to strengthen leadership across critical business units.
New Appointment in Oncology Leadership
The Board of Directors approved the appointment of Dr. Shashank Srinivasan as Medical Director – Oncology Business Unit, effective April 1, 2026. Dr. Srinivasan is an accomplished clinical oncologist, previously serving as the Interim Medical Director for Oncology at AstraZeneca India. His background includes significant industry leadership roles at Pfizer and extensive experience in strategic portfolio management and evidence generation.
Promotion in Market Access
Furthermore, the company confirmed the promotion of Mr. Venkat Natarajan. Effective April 1, 2026, he moves from his role as Lead – Market Access to the position of Director – Market Access Business Unit. Mr. Natarajan is recognized as a seasoned Market Access professional, having been instrumental since joining in January 2024 in building the function, driving strategic access initiatives, and securing product listings across various states.
Profile Highlights
Both roles are classified as Senior Management Personnel positions. Dr. Srinivasan brings a deep clinical and translational background, having worked at Tata Memorial Hospital and leading major therapy areas previously. Mr. Natarajan possesses nearly two decades of pharmaceutical industry experience, holding advanced management qualifications and specializing in pricing, patient affordability, and securing market access for new launches across Asia and Eastern Europe.
The company confirmed that both appointments are for a Full – time employment term, and neither individual has any direct disclosure of relationships between directors that need to be reported.
Source: BSE
